Royalty Pharma (NASDAQ:RPRX) Posts Earnings Results, Beats Estimates By $0.16 EPS

Royalty Pharma (NASDAQ:RPRX) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16, Zacks reports. Royalty Pharma had a return on equity of 24.65% and a net margin of 50.53%.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $31.72 on Tuesday. The firm has a market capitalization of $18.69 billion, a price-to-earnings ratio of 16.44 and a beta of 0.49. Royalty Pharma has a 1 year low of $24.05 and a 1 year high of $32.21. The business has a 50 day simple moving average of $27.93 and a 200-day simple moving average of $27.65. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.77%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is presently 43.52%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on RPRX shares. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.